Allergic rhinoconjunctivitis (ARC) presents as nasal symptoms, eye watering and additional signs of ocular allergy (e.g. itchy/burning eyes). Intranasal corticosteroids (INSs) are the most effective treatment for the nasal symptoms of seasonal allergic rhinitis (SAR; based on 4 meta-analyses) and are considered first-line therapy when nasal congestion forms a substantial component of the patient’s rhinitis symptoms. Clinical trial evidence shows that INSs also provide some relief from ocular symptoms of SAR and seasonal ARC in adults. INSs probably alleviate eye watering, the main ocular symptom of SAR, by relieving nasal congestion. Other ocular symptoms also improve with INSs. The mechanism for this effect is unknown, but might relate to naso-ocular reflex reduction. There are limited data on ocular safety with INSs. However, the literature supports the use of INSs over several months as there appears to be no considerable increase in the risk of ocular hypertension or glaucoma.

1.
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466–476.
2.
Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al: Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005;60:882–887.
3.
Bousquet J, Knani J, Hejjaoui A, Ferrando R, Cour P, Dhivert H, et al: Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen. Allergy 1993;48:183–188.
4.
Bielory L: Ocular allergy overview. Immunol Allergy Clin North Am 2008;28:1–23.
5.
Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC: A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(suppl 85):17–25.
6.
Meltzer EO: Allergic rhinitis: the impact of discordant perspectives of patient and physician on treatment decisions. Clin Ther 2007;29:1428–1440.
7.
Majani G, Baiardini I, Giardini A, Senna GE, Minale P, D’Ulisse S, et al: Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy 2001;56:313–317.
8.
Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B: Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182–188.
9.
Scadding GK, Williams A: The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology 2008;46:99–106.
10.
Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F: Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:1391–1396.
11.
Meltzer EO, Nathan RA, Selner JC, Storms W: Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997;99:S815–S819.
12.
Pratt EL, Craig TJ: Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol 2007;7:249–256.
13.
Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381–387.
14.
Bielory L: Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541–553.
15.
Virchow JC, Kay S, Demoly P, Mullol J, Canonica W, Higgins V: Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ 2011;14:305–314.
16.
Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624–1629.
17.
Bielory L: Intranasal corticosteroids and the eye: from negative ocular effects to clinical efficacy as a class effect. Ann Allergy Asthma Immunol 2008;100:506–508.
18.
Schenkel E, LaForce C, Gates D: Mometasone furoate nasal spray in seasonal allergic rhinitis – effective in relieving ocular symptoms. Allergy Clin Immunol Int 2007;19:50–53.
19.
Bielory L: Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008;100:272–279.
20.
Prenner BM, Lanier BQ, Bernstein DI, Shekar T, Teper A: Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2010;125:1247–1253.
21.
Bielory L, Chun Y, Bielory BP, Canonica GW: Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy 2011;66:686–693.
22.
Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, van Oene C, et al: Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078–1084.
23.
Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE: Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430–1437.
24.
Naclerio R, Kaiser H, Lumry W, Philpot E, Toler T, Ellsworth A: Fluticasone furoate nasal spray provided 24-hour relief of nasal and ocular symptoms of seasonal allergic rhinitis (SAR) caused by ragweed. Allergy 2007;62:134.
25.
Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W, et al: Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216–225.
26.
Jacobs R, Martin B, Hampel F, Toler W, Ellsworth A, Philpot E: Effectiveness of fluticasone furoate 110 µg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 2009;25:1393–1401.
27.
Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, et al: Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 2009;30:128–138.
28.
Amar NJ, Kaiser HB, Vandewalker ML, Toler WT, Prillaman BA, Philpot EE: Fluticasone furoate nasal spray provides better relief from the nighttime symptoms of seasonal allergic rhinitis (SAR) than oral fexofenadine. Ann Allergy Asthma Immunol 2009;102:A11.
29.
Bernstein DI, Levy AL, Hampel FC, Baidoo CA, Cook CK, Philpot EE, et al: Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952–957.
30.
DeWester J, Philpot EE, Westlund RE, Cook CK, Rickard KA: The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331–337.
31.
Moller C, Ahlstrom H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H: Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003;33:816–822.
32.
Condemi J, Schulz R, Lim J: Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000;84:533–538.
33.
Beswick KB, Kenyon GS, Cherry JR: A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985;9:560–567.
34.
Giger R, Pasche P, Cheseaux C, Cantini L, Rossetti A, Landis BN, et al: Comparison of once- versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol 2003;260:135–140.
35.
Rodrigo GJ, Neffen H: Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy 2011;41:160–170.
36.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8–160.
37.
Blaiss MS: Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin 2008;24:821–836.
38.
Bielory L, Lien KW, Bigelsen S: Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215–228.
39.
Bonini S: Allergic conjunctivitis: the forgotten disease. Chem Immunol Allergy 2006;91:110–120.
40.
Naclerio R: Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:129–139.
41.
Baroody FM, Foster KA, Markaryan A, deTineo M, Naclerio RM: Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194–199.
42.
Scadding GK, Keith PK: Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother 2008;9:2707–2715.
43.
Callebaut I, Spielberg L, Hox V, Bobic S, Jorissen M, Stalmans I, et al: Conjunctival effects of a selective nasal pollen provocation. Allergy 2010;65:1173–1181.
44.
Bielory L: Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect. J Allergy Clin Immunol 2008;121:538–539.
45.
Keith PK, Scadding GK: Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin 2009;25:2021–2041.
46.
Maspero J, Walters R, Wu W, Philpot E, Naclerio R, Fokkens W: An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc 2010;31:483–492.
47.
Baroody FM, Shenaq D, deTineo M, Naclerio R: Intranasal fluticasone furoate (FF) reduces eye symptoms after nasal allergen challenge (NAC). J Allergy Clin Immunol 2008;121:S151.
48.
Wagenmann M, Baroody FM, Desrosiers M, Hubbard WC, Ford S, Lichtenstein LM, et al: Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. Clin Exp Allergy 1996;26:371–378.
49.
Allen A, Down G, Newlands A, Rousell V, Salmon E: Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007;98:A89.
50.
Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, et al: Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071–1077.
51.
Allen DB: Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106:S179–S190.
52.
Passalacqua G, Albano M, Canonica GW, Bachert C, van Cauwenberge P, Davies RJ, et al: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:16–33.
53.
Benninger MS, Ahmad N, Marple BF: The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739–750.
54.
European Medicines Agency Pharmacovigilance Working Party: Corticosteroids for inhalational or intranasal use – risk of psychiatric, behavioural and other systemic adverse reactions. 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/11/WC500099367.pdf).
55.
European Glaucoma Society: Terminology and Guidelines for Glaucoma, ed 3. Savona, Dogma, 2008.
56.
Bielory L, Blaiss M, Fineman SM, Ledford DK, Lieberman P, Simons FE, et al: Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2006;96:514–525.
57.
Garbe E, Suissa S, LeLorier J: Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539–543.
58.
Cumming RG, Mitchell P: Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999;20:77–84.
59.
Mitchell P, Cumming RG, Mackey DA: Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999;106:2301–2306.
60.
Duh MS, Walker AM, Lindmark B, Laties AM: Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol 2000;85:356–361.
61.
Jick SS, Vasilakis-Scaramozza C, Maier WC: The risk of cataract among users of inhaled steroids. Epidemiology 2001;12:229–234.
62.
Smeeth L, Boulis M, Hubbard R, Fletcher AE: A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003;87:1247–1251.
63.
Garbe E, LeLorier J, Boivin JF, Suissa S: Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722–727.
64.
Ernst P, Baltzan M, Deschenes J, Suissa S: Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168–1174.
65.
Summary of Product Characteristics. AVAMYS 27.5 micrograms/spray nasal spray suspension (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000770/WC500028814.pdf), last updated 5/3/2011.
66.
Bielory L, Katelaris CH, Lightman S, Naclerio RM: Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 2007;9:35
67.
Bui CM, Chen H, Shyr Y, Joos KM: Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005;116:1042–1047.
68.
Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, Mela EK, Goumas PD, Gartaganis SP: The effect of nasal steroid administration on intraocular pressure. Ear Nose Throat J 2007;86:394–395.
69.
Bernstein D: Long-term ocular safety of mometasone furoate nasal spray during treatment of perennial allergic rhinitis. Allergy 2008;63:S87.
70.
Ozturk F, Yuceturk AV, Kurt E, Unlu HH, Ilker SS: Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J 1998;77:846–851.
71.
Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, Arrieta-Gomez JR, Astorga del Toro R, Bravo-Escobar G: Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004;130:187–191.
72.
Chervinsky P, Kunjibettu S, Miller DL, Prenner BM, Raphael G, Hall N, et al: Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:69–76.
73.
Ratner PH, Meltzer EO, Teper A: Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 2009;73:651–657.
74.
Derby L, Maier WC: Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000;105:912–916.
75.
Banov CH, Woehler TR, LaForce CF, Pearlman DS, Blumenthal MN, Morgan WF, et al: Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994;73:240–246.
76.
Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R: Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009;14:983–990.
77.
Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N: Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001;51:400–409.
78.
Valotis A, Högger P: Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007;8:54.
79.
Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004;60:265–268.
80.
Villa E, Magnoni M, Micheli D, Canonica G: A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother 2011;12:2107–2117.
81.
Haimovici R, Gragoudas ES, Duker JS, Sjaarda RN, Eliott D: Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology 1997;104:1653–1660.
82.
Brandt BM, Mandleblatt J, Asbell PA: Risk factors for herpes simplex-induced keratitis: a case-control study. Ann Ophthalmol 1994;26:12–16.
83.
Prabriputaloong T, Margolis TP, Lietman TM, Wong IG, Mather R, Gritz DC: Atopic disease and herpes simplex eye disease: a population-based case-control study. Am J Ophthalmol 2006;142:745–749.
84.
Kalpaklioglu AF, Kavut AB: Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis. Am J Rhinol Allergy 2010;24:29–33.
85.
Kaliner MA, Storms W, Tilles S, Spector S, Tan R, LaForce C, et al: Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 2009;30:255–262.
86.
Anolik R, Pearlman D, Teper A, Gates D: Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc 2009;30:406–412.
87.
Vasar M, Houle P-A, Douglass JA, Meltzer EO, Silvey MJ, Wu W, et al: Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 2008;29:313–321.
88.
Keith P, Lee LA: Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently. J Allergy Clin Immunol 2011;127:288–289.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.